Open-Label Arm of Ph 2 KeyVibe-002 Trial of MK-7684A (Coformulation of Vibostolimab and Keytruda) to continue in Previously Treated mNSCLC Patients March 31, 2023
Ph 1b/2 Study initiated to Evaluate Pepinemab + Avelumab in 2L Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients March 31, 2023
Ph 1/2 clinical trials of GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients discontinued March 31, 2023
First Patient dosed in FRIDA, a Ph Ib trial with iadademstat in R/R FLT3-mutant AML patients March 31, 2023
Ph 2/3 Trial for Eftilagimod Alpha plus Paclitaxel initiated in Metastatic Breast Cancer March 31, 2023
First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine March 31, 2023
Enrollment initiated in Ph 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer March 15, 2023
Ph 3 KEYNOTE-671 Trial Met Primary Endpoint of EFS in Patients With Resectable Stage II, IIIA or IIIB NSCLC March 15, 2023
Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Mets from NSCLC March 15, 2023
First Patient dosed in Ph 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer February 28, 2023
Trilaciclib Ph 3 PRESERVE 1 trial in CRC patients to discontinue after absence of efficacy signals in early data February 22, 2023
Ph 3 Study of Uproleselan in R/R AML to continue to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee February 22, 2023
Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer February 22, 2023
First Patient Dosed in ASPEN-07 Ph 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer February 22, 2023
Ph 2 Trial for ART0380 + Gemcitabine in Patients with Platinum-Resistant Ovarian Cancer initiated February 22, 2023
